CLINICAL_TRIALS
trial_result
· 2012-11-09
Clinical Trial Update: Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer [Phase 2]
Summary
A Phase 2 clinical trial evaluating aminocamptothecin for recurrent or unresectable epithelial ovarian cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: NYU Langone Health | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED